Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal up40.100 +1.000 (+2.558%)

14/09/2021 15:36

Genscript Bio (01548) unit starts phase 1 clinical trial

[ET Net News Agency, 14 September 2021] Genscript Biotech Corporation (01548) said
Legend Biotech Corporation (Legend Biotech), a non-wholly owned subsidiary of the company,
announced the start of a Phase 1 clinical trial in the United States for LB1901, an
investigational autologous CD4-targeted chimeric antigen receptor T-cell (CAR-T) therapy
for the treatment of adults with relapsed or refractory peripheral T-cell lymphoma (PTCL)
or cutaneous T-cell lymphoma (CTCL).
LB1901 targets CD4, a surface membrane glycoprotein uniformly expressed in most TCL
subtypes. The trial follows the U.S. Food and Drug Administration (the FDA) clearance of
the Investigational New Drug (the IND) application submitted by Legend Biotech. (RC)

Remark: Real time quote last updated: 26/11/2021 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.